Project Grant F31CA294736

Award Date 12/1/24
Completion Date 8/31/27
Dollars Obligated $87K
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
ROXBURY CROSSING, MA 02120, USA
Similar Awards
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program will provide $147,656 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to study the role of stress granules in cancer initiation. The overarching goal is to determine how stress granules, which are cytoplasmic aggregates formed upon cell stress, can enhance the viability and oncogenicity of melanoma precursor cells, thereby accelerating tumor...
This Project Grant award of $1,824,208, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), supports research focused on understanding the molecular mechanisms driving melanoma progression and tumor immune evasion. The Wistar Institute of Anatomy and Biology, the primary awardee, will lead this 5-year study to investigate how the transcription factor TFEB regulates melanoma cell plasticity and impacts the tumor microenvironment. A sub-award to the University of...
This $463,375 federal Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health program (CFDA 93.113) supports research at the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The research aims to identify and characterize the role of melanin-carbonyl-DNA (MCD) and melanin-carbonyl-protein (MCP) adducts in the progression and treatment resistance of NRAS mutant melanoma. The key objectives are to...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $442,236 to the University of Alabama at Birmingham to investigate the role of the YTHDF1 RNA-binding protein in driving melanoma metastasis. The research aims to determine how YTHDF1 promotes melanoma cell anoikis resistance and suppresses natural killer cell-mediated anti-tumor immunity, with a focus on the downstream mediators IMPDH1 and the TRKB/BDNF pathway. The project will...
The National Cancer Institute (NCI) awarded a $395,509 Project Grant under CFDA 93.396 "Cancer Biology Research" to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct research on targeting the SKP2 axis for anti-melanoma therapy. The research aims to: 1) investigate how the dysregulated RNF12-SKP2 E3 ligase cascade promotes melanoma tumorigenesis, and 2) examine how SKP2-mediated degradation of the tumor suppressor HHIP plays a role in melanoma development. The project...
This Project Grant award of $3,510,000.00 from the National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), supports research conducted by the Sanford Burnham Prebys Medical Discovery Institute (SBP) in La Jolla, California. The research focuses on understanding the mechanisms underlying melanoma metastasis and resistance, particularly the effects of aging on tumor-intrinsic factors like the UPR signaling component ATF4, as well as tumor-extrinsic...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $329,622 to the Icahn School of Medicine at Mount Sinai to conduct research on Merkel cell polyomavirus T-antigen mediated reprogramming in adult epidermis. The goal is to leverage a mouse model to generate novel insights into the mechanisms of T-antigen-driven cell reprogramming that contribute to Merkel cell carcinoma, a rare and poorly understood type of skin cancer. The...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $673,526.00 to the University of Pittsburgh to conduct research on the role of zinc metabolism in therapy-resistant melanoma. The key focus is to explore how the loss of the p16 gene, which occurs in approximately 40% of melanoma cases, leads to changes in zinc transport and homeostasis that impair the effectiveness of immune checkpoint blockade (ICB) therapy. The research plan aims to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for $1,419,108 will support research to advance the understanding of how a novel neoadjuvant therapy impacts the immune system in patients with solid tumors, using refractory melanoma as a model. The research, led by Emory University, will use surgical tissue specimens from a clinical trial to gain insights into how blocking the SEMA4D signaling pathway in combination with immune checkpoint...
This $167,000 federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research at Cedars-Sinai Medical Center to develop a novel combinatorial immunotherapeutic strategy for treating metastatic uveal melanoma. The research aims to first use a tumor debulking approach with the drug combination of trametinib and panobinostat to reduce tumor load, and then apply B7-H3 chimeric antigen receptor (CAR) T-cell therapy to...

INVESTIGATING MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR (MITF) AND GROWTH FACTORS AS INITIATORS OF MELANOMA - ABSTRACT MELANOMA IS THE DEADLIEST TYPE OF SKIN CANCER. IT CAN BE CURED WITH SURGICAL RESECTION IF DETECTED EARLY, SO ADVANCING METHODS OF PREVENTION AND EARLY DETECTION FOR MELANOMA IS CRITICAL. TO MODEL HUMAN MELANOMA, THE ZON LAB DEVELOPED A ZEBRAFISH MODEL WITH MELANOCYTES EXPRESSING HUMAN BRAFV600E IN A P53 NULL BACKGROUND (BRAFV600E;P53-/-). THE TUMORS FORMED WITH THIS ZEBRAFISH MODEL GENETICALLY AND HISTOLOGICALLY RESEMBLE HUMAN MELANOMA, AND THE TRANSPARENCY OF ZEBRAFISH MAKES THEM OPTIMAL MODELS FOR STUDYING MELANOMA INITIATION. WE CAN IMAGE MELANOCYTES IN ZEBRAFISH USING TG(MITFA:MCHERRY) TO EXPRESS MCHERRY FLUORESCENT PROTEIN UNDER THE CONTROL OF THE PROMOTER FOR MITFA, THE ZEBRAFISH ORTHOLOG OF THE HUMAN MITF GENE. WHEN IMAGING BRAFV600E;P53- /- ZEBRAFISH OVER TIME, WE INITIALLY OBSERVE HIGH AREAS OF MITFA EXPRESSION, WHICH WE CALL CANCER PRECURSOR ZONES (CPZS). SOME CPZS PROGRESS TO FORM TUMORS, WHILE OTHERS REMAIN GROWTH ARRESTED. CPZS THAT FORM TUMORS REACTIVATE AN EMBRYONIC NEURAL CREST PROGENITOR STATE. INCREDIBLY, IMAGING THE FLUORESCENT REPORTER TG(CRESTIN:EGFP) ALLOWS FOR THE IDENTIFICATION AND TRACKING OF THE SINGLE CELL INITIATING MELANOMA SINCE 100% OF MELANOCYTES EXPRESSING CRESTIN GO ON TO FORM TUMORS. BECAUSE NEURAL CREST REACTIVATION IS THE DEFINING TRANSFORMATIVE STEP FOR CPZS TO BECOME TUMORS, UNDERSTANDING THE MECHANISM OF THIS TRANSITION IS CRUCIAL, AND IT MAY REVEAL TARGETABLE PATHWAYS TO PREVENT MELANOMA. I AM INTERESTED IN THE EXTRACELLULAR MICROENVIRONMENT'S ROLE IN THE NEURAL CREST REACTIVATION OF CPZS. BY TRANSPLANTING CPZS, I OBSERVED THAT CPZ MELANOCYTES WITH HIGH MITFA:MCHERRY EXPRESSION APPEAR TO HAVE LOWER MITFA EXPRESSION FOLLOWING TRANSPLANT. ONE POSSIBLE CAUSE FOR THIS IS THE ABSENCE OF LIGANDS KNOWN TO REGULATE MITFA ACTIVITY WHEN MELANOCYTES ARE REMOVED FROM THEIR CPZ MICROENVIRONMENT. UPSTREAM PATHWAYS KNOWN TO REGULATE MITFA GENE TRANSCRIPTION INCLUDE C-KIT, WNT, AND CAMP. I HYPOTHESIZE THAT MITFA EXPRESSION CHANGES DURING NEURAL CREST REACTIVATION DUE TO THE ABSENCE OF C-KIT, WNT, AND CAMP REGULATORY LIGANDS. IN AIM 1, I WILL TEST THIS BY LOOKING AT PROTEIN AND RNA CHANGES TO MITFA AFTER TRANSPLANTS, CHEMICALLY PROVIDING CPZ MELANOCYTES WITH LIGANDS FOR C-KIT, WNT, AND CAMP PATHWAYS, AND USING A TEMPERATURE SENSITIVE MITFA MUTANT. A SECOND PRELIMINARY OBSERVATION WAS CPZ MELANOCYTES EXPRESSING CRESTIN WITHIN SEVEN DAYS OF TRANSPLANT, FASTER THAN USUALLY OBSERVED IN ZEBRAFISH. SINCE MELANOCYTES ARE TRANSPLANTED IN GROWTH-FACTOR RICH MATRIGEL, I HYPOTHESIZE THAT SPECIFIC GROWTH FACTORS IN MATRIGEL DIRECT MELANOCYTES TO INITIATE MELANOMA. IN AIM 2, I WILL TEST THIS BY PERFORMING PROTEOMICS AND SINGLE CELL RNA SEQUENCING TO IDENTIFY PROTEINS THAT CONTRIBUTE TO CRESTIN INDUCTION AND THEIR CELLULAR SOURCES. THESE PROTEINS WILL BE FURTHER INVESTIGATED WITH CHEMICAL AND GENETIC APPROACHES TO TEST THEIR SUFFICIENCY FOR NEURAL CREST REACTIVATION FROM CPZS. COLLECTIVELY, INVESTIGATING THE CONTRIBUTION OF MITFA AND GROWTH FACTORS TO NEURAL CREST REACTIVATION WILL ADVANCE UNDERSTANDINGS OF THE MECHANISMS UNDERLYING MELANOMA INITIATION AND CONTRIBUTE TO A BROAD EFFORT TO UNDERSTAND THE DRIVERS OF THIS COMPLEX PROCESS IN VIVO.

Posted 6/24/24, 12:00 AM